Global Neuroendocrine Tumor Treatment Markets, Trends, Competition, Opportunity and Forecast, 2028F - Advancements in Neuroendocrine Tumor Treatments Spur Market Expansion

News provided by

Aug 08, 2023, 11:00 ET

DUBLIN, Aug. 8, 2023 /PRNewswire/ -- The "Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition" report has been added to ResearchAndMarkets.com's offering.

Global neuroendocrine tumor treatment market is anticipated to experience growth to 2028

This can be attributed to the rising prevalence of neuroendocrine tumors across the globe. The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022, titled "Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)".

Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market's growth.

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years.

This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market.

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021.

Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million.

Moreover, for the project `Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial,` Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global neuroendocrine Tumor treatment market.

F Hoffmann-La Roche AG
Bristol-Myers Squibb Co
Eli Lilly & Co
Novartis AG
Pfizer Inc
Amgen Inc
Exelixis Inc
Teva Pharmaceutical Industries Ltd
AVEO Pharmaceuticals Inc
Hutchison MediPharma Ltd

Market Dynamics

Drivers

Developments and Approval of Novel Drugs
Use of Artificial Intelligence (AI) in Treatment Techniques
Increased Government and Company's' Initiatives

Market Trends & Developments

Upcoming Patient Assistance Programs (PAPs)
Ongoing Clinical Trials and R&D Programs
Adoption of Next-Generation Sequencing Techniques

Challenges

High Cost of the Treatment
Associated Side Effects of the Treatment
Stringent Regulatory Framework

Clinical Trial Analysis

Ongoing Clinical Trials
Completed Clinical Trials
Terminated Clinical Trials
Breakdown of Pipeline, By Development Phase
Breakdown of Pipeline, By Status
Breakdown of Pipeline, By Site Analysis
Breakdown of Pipeline, By Region
Clinical Trials Heat Map

Report Scope:

Neuroendocrine Tumor Treatments Market, By Product Analysis:

Somatostatin Analogs (SSA)
Targeted Therapy
Others

Neuroendocrine Tumor Treatments Market, By Site Analysis:

Lungs
Pancreas
Colon
Small Intestine
Others

Neuroendocrine Tumor Treatments Market, By End User:

Hospitals & Clinics
Ambulatory Care Centers
Others

Neuroendocrine Tumor Treatments Market, By Region:

Asia-Pacific
China
India
Japan
South Korea
Australia
Europe
France
Germany
United Kingdom
Italy
Spain
North America
United States
Mexico
Canada
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

For more information about this report visit https://www.researchandmarkets.com/r/s2j5rz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets